These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 9010146

  • 1. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.
    Fanucchi M, Glaspy J, Crawford J, Garst J, Figlin R, Sheridan W, Menchaca D, Tomita D, Ozer H, Harker L.
    N Engl J Med; 1997 Feb 06; 336(6):404-9. PubMed ID: 9010146
    [Abstract] [Full Text] [Related]

  • 2. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia--a randomized, placebo-controlled, double-blind safety and efficacy study.
    Geissler K, Yin JA, Ganser A, Sanz MA, Szer J, Raghavachar A, Hoelzer D, Martinez C, Taylor K, Kanz L, To LB, Archimbaud E.
    Ann Hematol; 2003 Nov 06; 82(11):677-83. PubMed ID: 14530872
    [Abstract] [Full Text] [Related]

  • 3. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
    Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Grigg AP, Zalcberg J, Cohen B, O'Byrne J, Menchaca DM, Fox RM, Begley CG.
    Blood; 1997 May 01; 89(9):3118-28. PubMed ID: 9129014
    [Abstract] [Full Text] [Related]

  • 4. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
    Schuster MW, Beveridge R, Frei-Lahr D, Abboud CN, Cruickshank S, Macri M, Menchaca D, Holden J, Waller EK.
    Exp Hematol; 2002 Sep 01; 30(9):1044-50. PubMed ID: 12225796
    [Abstract] [Full Text] [Related]

  • 5. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation.
    Bolwell B, Vredenburgh J, Overmoyer B, Gilbert C, Chap L, Menchaca DM, Cruickshank S, Glaspy J.
    Bone Marrow Transplant; 2000 Jul 01; 26(2):141-5. PubMed ID: 10918423
    [Abstract] [Full Text] [Related]

  • 6. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice.
    Kabaya K, Shibuya K, Torii Y, Nitta Y, Ida M, Akahori H, Kato T, Kusaka M, Miyazaki H.
    Bone Marrow Transplant; 1996 Dec 01; 18(6):1035-41. PubMed ID: 8971370
    [Abstract] [Full Text] [Related]

  • 7. PEG-rHuMGDF ameliorates thrombocytopenia in carboplatin-treated rats without inducing myelofibrosis.
    Ide Y, Harada K, Imai A, Yanagida M.
    Int J Hematol; 1999 Aug 01; 70(2):91-6. PubMed ID: 10497847
    [Abstract] [Full Text] [Related]

  • 8. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.
    Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Hussein S, Alt C, Menchaca D, Tomita D, Marty J, Fox RM, Begley CG.
    Lancet; 1996 Nov 09; 348(9037):1279-81. PubMed ID: 8909381
    [Abstract] [Full Text] [Related]

  • 9. [A multi-center clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor].
    Bai CM, Xu GX, Zhao YQ, Han SM, Shan YD.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug 09; 26(4):437-41. PubMed ID: 15379272
    [Abstract] [Full Text] [Related]

  • 10. Systemic effects of pegylated recombinant human megakaryocyte growth and development factor in combination with recombinant murine granulocyte colony-stimulating factor in a murine model of myelosuppression.
    Coleman D, Fairchild D, Schindler-Horvat J, Munyakazi L, Neumann TA.
    Toxicol Sci; 1998 Sep 09; 45(1):77-87. PubMed ID: 9848114
    [Abstract] [Full Text] [Related]

  • 11. Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice.
    Akahori H, Shibuya K, Ozai M, Ida M, Kabaya K, Kato T, Miyazaki H.
    Stem Cells; 1996 Nov 09; 14(6):678-89. PubMed ID: 8948025
    [Abstract] [Full Text] [Related]

  • 12. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice.
    Kabaya K, Akahori H, Shibuya K, Nitta Y, Ida M, Kusaka M, Kato T, Miyazaki H.
    Stem Cells; 1996 Nov 09; 14(6):651-60. PubMed ID: 8948023
    [Abstract] [Full Text] [Related]

  • 13. [Evaluation of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in lung cancer patients].
    Xu YH, Chen ZW, Ye XY, Lu S.
    Zhonghua Zhong Liu Za Zhi; 2008 Sep 09; 30(9):716-9. PubMed ID: 19173920
    [Abstract] [Full Text] [Related]

  • 14. Overview of the safety and biologic effects of PEG-rHuMGDF in clinical trials.
    Sheridan W, Menchaca D.
    Stem Cells; 1998 Sep 09; 16 Suppl 2():193-8. PubMed ID: 11012191
    [Abstract] [Full Text] [Related]

  • 15. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
    Harker LA, Marzec UM, Kelly AB, Cheung E, Tomer A, Nichol JL, Hanson SR, Stead RB.
    Blood; 1997 Jan 01; 89(1):155-65. PubMed ID: 8978288
    [Abstract] [Full Text] [Related]

  • 16. Clinical studies with megakaryocyte growth and development factor (Mpl-ligand).
    Begley CG.
    Thromb Haemost; 1997 Jul 01; 78(1):42-6. PubMed ID: 9198125
    [Abstract] [Full Text] [Related]

  • 17. The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin.
    Smith JW, Longo DL, Alvord WG, Janik JE, Sharfman WH, Gause BL, Curti BD, Creekmore SP, Holmlund JT, Fenton RG.
    N Engl J Med; 1993 Mar 18; 328(11):756-61. PubMed ID: 8437596
    [Abstract] [Full Text] [Related]

  • 18. [The clinical study of recombinant human thrombopoietin in the treatment of chemotherapy-induced severe thrombocytopenia].
    Bai CM, Zou XY, Zhao YQ, Han SM, Shan YD, Thrombopoietin Clinical Trail Cooperation Group.
    Zhonghua Yi Xue Za Zhi; 2004 Mar 02; 84(5):397-400. PubMed ID: 15061993
    [Abstract] [Full Text] [Related]

  • 19. Early Australian clinical studies with pegylated recombinant human megakaryocyte growth and development factor.
    Basser RL.
    Stem Cells; 1998 Mar 02; 16 Suppl 2():225-9. PubMed ID: 11012194
    [Abstract] [Full Text] [Related]

  • 20. Use of PEG-rHuMGDF in platelet engraftment after autologous stem cell transplantation.
    Fields KK, Crump M, Bence-Bruckler I, Bernstein S, Williams S, Frankel S, Miller A, Demetri G, Nabholtz JM, Cruickshank S, Lill M.
    Bone Marrow Transplant; 2000 Nov 02; 26(10):1083-8. PubMed ID: 11108307
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.